JMP Securities Initiates Inhibrx at Market Perform
Inhibrx Initiated at Market Perform by JMP Securities
Inhibrx Biosciences Analyst Ratings
JMP Securities Maintains Inhibrx Biosciences(INBX.US) With Hold Rating
Inhibrx Biosciences: Hold Rating Justified by Financial Stability and Clinical Pipeline Potential
Inhibrx Biosciences Files to Sell 2.45M Shares of Common Stock for Holders
Inhibrx Biosciences(INBX.US) Director Buys US$997.02K in Common Stock
Express News | Inhibrx Biosciences 13G Filing Shows Viking Global Investors LP Reported A 12.3% Stake In The Co As Of May 29, 2024
Express News | Viking Global Investors LP Reports 12.3% Passive Stake in Inhibrx Biosciences, Inc. as of May 29, 2024- SEC Filing
Top 4 Health Care Stocks That Are Preparing To Pump This Month
Inhibrx Biosciences Insider Bought Shares Worth $4,927,580, According to a Recent SEC Filing
Express News | Trading Halt: Halt Status Updated at 8:40:00 AM ET: Quotation Resumption: News and Resumption Times
Inhibrx Biosciences Announces Major Corporate Restructuring Events
News On Inhibrx Biosciences Inc. (INXBV) Now Under INXB